National Cancer Institute (NCI): all 3,554 studies

Page 19 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
• A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersCompletedNCT04708470Phase 1/2
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaActive, not recruitingNCT04708418Phase 2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01TerminatedNCT04674228
• Assessing Sleep and Circadian Rhythms in Primary Brain Tumors PatientsCompletedNCT04669574
• Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 1
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 1
• Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
• Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT04595747Phase 2
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3
• Pomalidomide Treatment in Patients With Kaposi SarcomaActive, not recruitingNCT04577755Phase 2
• A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade GliomaActive, not recruitingNCT04576117Phase 3
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2
• Integrated Genomic Prostate Score With MRI Targeted Prostate BiopsiesActive, not recruitingNCT04541030
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedNCT04539366Phase 1
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabWithdrawnNCT04536922Phase 2
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingNCT04533750Phase 1
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingNCT04530565Phase 3
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of HysterectomyActive, not recruitingNCT04494113Early Phase 1
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)sTerminatedNCT04488263
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)TerminatedNCT04447014
• EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingNCT04444921Phase 3
• Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainCompletedNCT04442425
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell TransplantationWithdrawnNCT04428918
• Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingNCT04417660Phase 2
• E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial NeoplasiaWithdrawnNCT04411134Phase 1
• Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialSuspendedNCT04402788Phase 2/3
• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2
• NCI COVID-19 in Cancer Patients, NCCAPS StudyActive, not recruitingNCT04387656
• Testing the Safety of CB-5339 in Patients With CancerWithdrawnNCT04372641Phase 1
• Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 InfectionCompletedNCT04362865
• Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)Active, not recruitingNCT04358107
• Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerActive, not recruitingNCT04334941Phase 2
• Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLActive, not recruitingNCT04324112Phase 2
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingNCT04317105Phase 1/2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
• Testing the Biological Effects of DS-8201a on Patients With Advanced CancerActive, not recruitingNCT04294628Phase 1
• M7824 Related Adverse Effects in Adults With CancerActive, not recruitingNCT04267861
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3
• Radium-223 in Biochemically Recurrent Prostate CancerActive, not recruitingNCT04206319Phase 2
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04190550Phase 1
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedNCT04172532Phase 1/2
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerCompletedNCT04145141
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT CarcinomaWithdrawnNCT04116359Phase 1/2
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the BonesActive, not recruitingNCT04090398Phase 2
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL StudyActive, not recruitingNCT04071223Phase 2
• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingNCT04068194Phase 1/2
• Vaccine Response With NT-I7WithdrawnNCT04054752Phase 1
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal CancerWithdrawnNCT04044950Phase 2
• Pediatric cGVHD Symptom ScaleActive, not recruitingNCT04044365
• Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) OralWithdrawnNCT04025567Phase 2
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasActive, not recruitingNCT03984448Phase 2/3
• Optimizing PTCy Dose and TimingActive, not recruitingNCT03983850Phase 1/2
• Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
• Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerActive, not recruitingNCT03976843Phase 2
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)Active, not recruitingNCT03964090Phase 2
• Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR SpectroscopySuspendedNCT03952598Phase 2
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaActive, not recruitingNCT03922724Phase 2
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaActive, not recruitingNCT03871257Phase 3
• Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedNCT03860987Phase 2
• Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
• Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With CancerActive, not recruitingNCT03827343
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
• TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsActive, not recruitingNCT03816319Phase 1
• Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerActive, not recruitingNCT03811015Phase 3
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT03798678Phase 1
• Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnNCT03794297Phase 2
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingNCT03775265Phase 3
• Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaWithdrawnNCT03748927
• Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
• Optimization of Collection Methods for Studies of the Human MicrobiotaWithdrawnNCT03731702
• Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialActive, not recruitingNCT03712605Phase 3
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyCompletedNCT03707574
• Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT03701321Phase 1/2

← National Cancer Institute (NCI) overview and focus areas